Damora Therapeutics (DMRA) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Damora Therapeutics (DMRA) over the past year, gaining 322.3% versus a gain of 12.9%. Over five years, OMER leads with a +142.6% price change compared with -76.3% for DMRA. Omeros is the larger company by market cap ($1.34 billion vs $1.20 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | OMER |
|---|---|---|
| Share price | $19.50 | $18.48 |
| Market cap | $1.20B | $1.34B |
| 1-day change | -3.64% | -1.44% |
| YTD return | -12.04% | +9.14% |
| 1-year return | +12.95% | +322.30% |
| 5-year return | -76.33% | +142.56% |
| P/E ratio (TTM) | — | 15.15 |
| Forward P/E | — | 15.02 |
| EPS (TTM) | $-0.25 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $21.24 |
| 52-week low | $4.95 | $4.06 |
| Distance from 52-week high | -49.12% | -12.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +140.46% | +48.81% |
| Average volume | 539.81K | 1.74M |
| Shares outstanding | 61.74M | 72.39M |
| Employees | 7 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed DMRA by 309.4 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
DMRA vs OMER FAQ
Which is bigger, Damora Therapeutics or Omeros?
Omeros (OMER) is larger, with a market capitalization of $1.34B compared with $1.20B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, DMRA or OMER?
OMER returned +322.30% over the past 12 months, compared with +12.95% for DMRA (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.